Clinical Trial

International Study for Treatment of High Risk Childhood Relapsed ALL 2010

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main goal of this study is to improve the outcome of children and adolescents with acute lymphoblastic leukemia with high risk first relapse by optimization of treatment strategies within a large international trial and the integration of new agents.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2018-07-17; most recent amendment 2026-03-16.
Trial Details
NCT Number NCT03590171
Lead Sponsor Charite University, Berlin, Germany
Collaborators: Australian & New Zealand Children's Haematology/Oncology Group, St. Anna Kinderkrebsforschung, CCRI (co-sponsor, Austria), European Organisation for Research and Treatment of Cancer - EORTC, University Hospital, Motol, Rigshospitalet, Denmark, Turku University Central Hospital (co-sponsor, Finland), Centre Hospitalier Universitaire de Nice, Our Lady's Chilrden's Hospital (Co-Sponsor Ireland), Tel Aviv Sourasky Medical Centre (Co-Sponsor Israel), Ospedale Pediatrico Bambino (co-sponsor, Italy), Prinses Máxima Centrum (Co-Sponsor Netherlands), Oslo University Hospital (co-sponsor, Norway), Wroclaw Medical University, Instituto Português de Oncologia de Lisboa (co-sponsor, Portugal), Karolinska University Hospital Stockholm (co-sponsor, Sweden), Spanish Society of Pediatric Hematology and Oncology (SEHOP) (Co-Sponsor Spain), University Children's Hospital, Zurich, Manchester University NHS Foundation Trust
Conditions Acute Lymphoblastic Leukemia (ALL)
Enrollment 250 participants
Start Date 2017-09-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-17